Mednet Logo
HomeNephrology
Nephrology

Nephrology

Clinical discussions on kidney disease management, dialysis, transplantation, and electrolyte disorders.

Recent Discussions

Do you recommend genetic testing for patients with a family history of polycystic kidney disease and who meet the imaging criteria, but the specific genetic variant in the family is unknown?

1
1 Answers

Mednet Member
Mednet Member
Nephrology · UCSF

This is an interesting and evolving area. I think this is somewhat dependent on a patient's own interest after discussing the following things: In some cases, even with family history and imaging criteria, a genetic diagnosis may not be available from testing (due to inability to detect or perhaps i...

Do you restrict topical diclofenac use in your patients with chronic kidney disease?

2
3 Answers

Mednet Member
Mednet Member
Nephrology · University Of California San Francisco Medical Center At Parnassus

It is a great question. I normally don't but I always do it with a touch of hesitation. I believe the absorption is minimal but it also depends of the degree of use. At this time, when narcotics are in restricted use and oral NSAIDs are not a good option in patients with CKD, topical NSAIDs may be t...

How frequently do you check serum electrolytes for patients on CRRT?

1 Answers

Mednet Member
Mednet Member
Nephrology · University Of California San Francisco Medical Center At Parnassus

When starting out CVVH and with unstable patients who have very abnormal electrolytes, as often as even every 6 hours. In patients who have been on stable dose of cvvh and electrolytes are within goal, even twice a day may be enough.

What is your approach to weight loss interventions for patients with recurrent nephrolithiasis and obesity?

1 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

Obesity tends to be a little more common in stone formers. Integrating weight loss with stone prevention features can be tricky. We are fortunate to have a dietitian dedicated to our Stone Clinic and I rely heavily upon her expertise. More fluid, preferably water, and a diet tailored to the patient’...

How would you manage persistent Norovirus diarrheal infections in a kidney transplant patient that are not responding to a decrease in the patient’s maintenance immunosuppressive regimen?

1
3 Answers

Mednet Member
Mednet Member
Infectious Disease · Johns Hopkins University

This is a difficult situation and does not have a strong evidence based response. First, I would really make sure they are not on mycophenolate as this is really the main problem with chronic Norovirus for most patients. Next, I would see if there are any available clinical trials that the patient m...

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

2
2 Answers

Mednet Member
Mednet Member
Rheumatology · Hackensack University Medical Center

I agree with @Dr. @Dr. First Last's previous answer (posted July 2020). In addition, the 2024 ACR Lupus Nephritis guidelines (discussed at the 2024 ACR meeting) still recommend mycophenolate (MMF) or cyclophosphamide as first-line induction therapies for lupus nephritis (LN), rather than B-cell depl...

Do you prefer celecoxib over a nonselective NSAID in patients with chronic kidney disease?

3
4 Answers

Mednet Member
Mednet Member
Rheumatology · Institute for Rheumatic & Autoimmune Diseases, Atlantic Health System

There are many potential advantages of celecoxib, as a "selective" COX-2 inhibitor, over non-selective NSAIDs. Because of the lesser inhibition of platelet function, it has potential advantages in the peri-operative period, in patients with bleeding disorders or taking anti-thrombotic or anti-coagul...

How do you choose between eculizumab and ravulizumab for patients with acute kidney injury from complement mediated thrombotic microangiopathy?

1 Answers

Mednet Member
Mednet Member
Nephrology · Columbia University

For atypical HUS (aka complement-mediated TMA), both eculizumab and ravalizumab are FDA-approved therapies and are technically equivalent.The main advantage of ravulizumab is that it is a re-engineered form of eculizumab that extends its half-life to 51.8 days vs 11.3 days for eculizumab.Of note, me...

Is there a role for 24 hour urine stone risk profiles in your patients with known recurrent struvite kidney stones?

1
1 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

It depends. Pure struvite stones are not a metabolic abnormality; they are the consequence of a urease-producing urinary infection that splits urea to ammonium, raising the urine pH into the high 7-8 range, which in turn precipitates magnesium ammonium phosphate, otherwise known as struvite. Pure st...

Is there a kidney stone size for which you refer your patients with recurrent nephrolithiasis to urology?

1
1 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

Predicting ureteral stone behavior is fraught with error. In general, stones less than or equal to 3 mm in maximum diameter will pass spontaneously if the patient can tolerate the pain. In fact, routine annual follow-up imaging occasionally shows the absence of small stones, but the patient has no m...